Helixgate

Helixgate

Uncategorized

STAT+: OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence

NEWARK, N.J. — OxyContin maker Purdue Pharma is set to be dissolved and replaced by a company focused on the public good by the week’s end, as a massive legal settlement resolving thousands of lawsuits takes effect.

A federal judge on Tuesday delivered a criminal sentence to the company to resolve a Department of Justice probe — a last necessary step to clear the way for the settlement.

U.S. District Judge Madeline Cox Arleo made her decision after listening to hours of impact statements from people who lost loved ones or struggled with addiction themselves and requested she reject the negotiated sentence. While she didn’t go that far, she said she sympathized with people who bore the brunt of an epidemic linked to more than 900,000 deaths in the U.S. since 1999.

Continue to STAT+ to read the full story…

Read More

Published

on

NEWARK, N.J. — OxyContin maker Purdue Pharma is set to be dissolved and replaced by a company focused on the public good by the week’s end, as a massive legal settlement resolving thousands of lawsuits takes effect.

A federal judge on Tuesday delivered a criminal sentence to the company to resolve a Department of Justice probe — a last necessary step to clear the way for the settlement.

U.S. District Judge Madeline Cox Arleo made her decision after listening to hours of impact statements from people who lost loved ones or struggled with addiction themselves and requested she reject the negotiated sentence. While she didn’t go that far, she said she sympathized with people who bore the brunt of an epidemic linked to more than 900,000 deaths in the U.S. since 1999.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Published

on

Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.​ ​Read More

Continue Reading

Uncategorized

Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy

Published

on

Eli Lilly’s new JAK2 inhibitor—which it obtained from the recent acquisition of Ajax Therapeutics—reduced spleen volume by more than a third in 70% of patients with myelofibrosis.

Continue Reading

Uncategorized

Celiac disease is entering a new era of therapeutic innovation

For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

Read More

Published

on

For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

Read More

Continue Reading
Advertisement

Trending